Early ravulizumab shows promise for speeding ICU recovery in myasthenia crisis
NCT ID NCT07411963
First seen Feb 27, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study looks at whether giving the drug ravulizumab early, after standard treatments, can help people with a life-threatening myasthenia gravis crisis recover faster in the ICU. About 30 adults in France will be observed for 6 months. The goal is to see if it reduces time on a breathing machine and shortens hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de NICE
RECRUITINGNice, Alpes-maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.